Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

signalling pathways 2013 banner

Platinum Sponsor

Astellas Pharma Europe Ltd.

2000 Hillswood Drive
Chertsey, Surrey, KT16 0RS
United Kingdom
Tel: +44 203 379 8000
Fax: +44 203 379 8001

About Astellas
Astellas is already an established player in the fields of Transplantation, Urology, Dermatology, Anti-Infectives and Pain Management. We are now bringing our expertise to the field of Oncology.
 With no fewer than 12 separate therapies currently under clinical development, we aim to fulfil not just our potential, but our promise to change tomorrow for patients suffering with conditions such as prostate cancer, advanced renal cell carcinoma and haematological malignancies.

Silver sponsors

Amgen (Europe) GmbH

Dammstrasse 23
6300 Zug
 Tel: +41 41 3690 300
Fax: +41 41 3690 400

About Amgen
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Merck Serono - Merck KGaA

64293 Darmstadt
 Tel: +49 6151 72-0
Fax: +49 6151 72-2000

About Merck Serono

Merck licensed the right to market Erbitux outside the US and Canada from ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, in 1998 In Japan, ImClone, Bristol-Myers Squibb Company and Merck jointly develop and commercialize Erbitux. Merck aquired the exclusive worldwide rights for development and commercialization of L-BLP25 from Oncothyreon Inc. in 2007. In Japan, Merck entered into a co-development and co-marketing agreement for L-BLP25 with Ono Pharmaceutical. Merck signed a license and co-development agreement for TH-302 with Threshold Pharmaceuticals Inc. in 2012.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.